Company profile
Amprologix - Antimicrobial prospecting and logical design
Amprologix Limited is a UK company with status active founded in 2018 based in South West England.
Financial period: 1 Jul 2024 to 30 Jun 2025
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
Amprologix develops antibiotics designed to treat infections resistant to traditional antibiotics.
A University of Plymouth spin out established to commercialize epidermicin IPR arising from work in University of Manchester and University of Plymouth.
Shortly after company formation, an award was made from the Department of Health and Social Care (via Innovate UK/SBRI) for a contract valued at £12.m to progress the lead compound (epidermicin) through pre-clinical development.
1 Jan 2024 to 31 Dec 2025
Amprologix is a company developing novel antibiotics to meet the global threat of antimicrobial resistance (AMR). AMR happens when bacteria become resistant to antibiotics and results in treatment failure and increased death from 'drug resistant' infections. These infections killed over 1.2 million people in 2019 and new antibiotics are urgently needed. I...
1 Feb 2019 to 30 Apr 2021
Antimicrobial resistant (AMR) bacteria kill over 25,000 people a year in Europe and resistance rates are climbing rapidly worldwide. There is a critical need for novel classes of antibiotics to tackle the rise of antibiotic resistant bacteria and serve as scaffolds for derivatisation, diversification and enhancement of efficacy, a strategy proven successf...
